Adverum Biotechnologies(ADVM)
搜索文档
Adverum Biotechnologies(ADVM) - 2023 Q4 - Annual Results
2024-03-19 04:08
Exhibit 99.1 Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates - Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 - - 1-for-10 reverse stock spl ...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Newsfilter· 2024-03-19 04:05
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 – - 1-for-10 reverse stock split to be effective March 21, 2024 - REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-st ...
Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop
InvestorPlace· 2024-03-07 04:07
There are plenty of penny stocks ready to pop. However, we have to remember that penny stocks are extremely risky, and can be costly in the end. So, one, never risk more than you can afford to lose on any penny stock. That’s even if you believe it’s a “sure thing.”Two, don’t just buy any penny stock out there. Make sure you do your due diligence. Three, take some advice from the SEC. “Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them. Be ...
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
Newsfilter· 2024-02-08 20:00
Adverum生物技术公司 - Adverum生物技术公司在湿性年龄相关性黄斑变性(AMD)患者中进行的LUNA Phase 2试验显示,两个剂量水平(2E11和6E10)展示了潜在的最佳临床活性,包括减轻治疗负担和维持视力和解剖终点[1] - 初步安全数据支持两个剂量水平具有有利的风险效益概况[1] - Ozurdex + difluprednate被确定为潜在的“前进”预防措施,大多数接受“前进”方案的患者没有炎症,超过90%的患者没有或轻微炎症[1] - Adverum生物技术公司的Ixo-vec在湿性AMD患者中展示了潜在的最佳临床活性,且早期疗效和安全数据趋势类似或优于OPTIC研究[1]
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
Newsfilter· 2024-02-05 20:45
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo Capital, as well two large investment management firms. - Pro forma cash and investments expected to fund current operating plan into late 2025. REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establi ...
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
Newsfilter· 2024-02-02 06:30
Adverum Biotechnologies公司 - Adverum Biotechnologies公司将在2024年2月8日举行网络研讨会,介绍Ixoberogene soroparvovec(Ixo-vec)用于治疗湿性年龄相关性黄斑变性(wet AMD)的LUNA Phase 2研究的初步疗效和安全性数据[1] - 由于Adverum Biotechnologies公司的LUNA研究已于2023年8月完全招募完成,因此将在Macula Society第47届年会上详细介绍这些初步结果[1] - Adverum将于2024年2月8日举行电话会议和网络研讨会,讨论Ixoberogene soroparvovec(Ixo-vec)LUNA Phase 2研究的初步安全性和疗效数据[3]
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
GlobeNewsWire· 2024-02-02 06:30
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the compa ...
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
Newsfilter· 2024-01-29 21:00
公司任命 - Adverum Biotechnologies, Inc.宣布Romuald "Romu" Corbau, Ph.D.加入公司担任首席科学官[1] 个人经历 - Romu在过去的职业生涯中领导了Spark Therapeutics的Luxturna®项目,是一种用于遗传性视力丧失的基因治疗产品[1] - Romu在GenEdit担任首席科学官之前,曾在Freeline和Spark Therapeutics等公司担任重要职务,积累了超过25年的行业经验[3]
Here's Why You Should Invest in Adverum (ADVM) Stock Now
Zacks Investment Research· 2024-01-04 22:47
基因疗法开发 - Adverum Biotechnologies (ADVM) 正在开发单次注射基因疗法,主要针对高发性眼部疾病[1] - Ixo-vec 被设计为在医生办公室进行一次性注射,可以减轻频繁抗血管内皮生长因子(VEGF)注射的负担[2] 临床研究结果 - OPTIC 和 LUNA 两项临床研究中,OPTIC 延长研究的长期数据表明,患有潮湿型AMD的患者在三年的随访中持续获益[3]
Adverum Biotechnologies(ADVM) - 2023 Q3 - Quarterly Report
2023-11-09 00:00
产品及临床试验 - Adverum是一家临床阶段公司,旨在将基因疗法确立为高患病率眼部疾病的新标准[59] - Ixo-vec是Adverum的主力产品候选药物,旨在为湿性年龄相关性黄斑变性患者提供长期持久的治疗效果[61] - Ixo-vec在OPTIC试验中显示出治疗效果的强烈信号,包括稳定的aflibercept蛋白水平和改善的视力[63] - LUNA试验已完成招募,初步数据显示两个剂量的Ixo-vec均提供处于治疗范围内的aflibercept水平[67] - FDA授予Ixo-vec快速通道设计,EMA授予PRIME设计,MHRA授予创新护照[69,70,71] - ADVM-062是Adverum的第二个产品候选药物,旨在治疗蓝锥单色视觉障碍[74] - Adverum在干性AMD/地理性萎缩项目和光遗传学项目方面取得进展[76,77] 财务状况 - Adverum的财务状况显示累积赤字达8.961亿美元,预计将继续面临财务压力[79,82] - Adverum目前没有从产品销售中产生任何收入,主要通过研究、合作和许可安排获得收入[84] - 研发费用主要包括人员相关成本、股权补偿费用、实验室用品、咨询费用、外部合同研发费用等[85] - 研发费用按发生时计入,预付的货物或服务费用将随着货物交付或相关服务完成而计入[86] - 无法合理估计完成任何产品候选品开发所需的工作性质、时间或总成本[88] - 行政费用主要包括人员相关成本、股权补偿、法律、咨询、审计和税务服务的专业费用等[89] - 其他收入(费用)主要包括我们现金等价物和可交易证券的利息收入[90] - 我们的财务状况和运营结果的讨论和分析基于我们的未经审计的简明合并财务报表[91] - 我们在简明合并资产负债表上确认租赁权益资产和租赁负债[92] - 租赁费用按直线法在租赁期内确认,并计入营业费用[93] - 租赁收入按概率收集的概率分类为减少营业费用[94] - 我们的研发费用在2023年9月30日和2022年9月30日的三个和九个月的比较中有所下降[95] 现金流及投资活动 - 2022年9月30日,公司经营活动产生的净现金流为89.6百万美元,主要是由于公司产品候选者开发活动持续导致的净损失为121.8百万美元,部分抵消了20.0百万美元的非现金费用,主要涉及14.8百万美元的股票补偿费用、4.8百万美元的折旧和摊销费用、3.1百万美元的非现金租赁费用以及2.0百万美元的长期资产减值,以及12.2百万美元的营运资产和负债变动[107] - 2023年9月30日,公司投资活动提供的净现金为107.4百万美元,主要来自于我们的有价证券净到期,部分抵消了0.6百万美元的相关固定资产购买[108] - 2022年9月30日,公司投资活动提供的净现金为151.1百万美元,主要来自于我们的有价证券净到期,部分抵消了11.6百万美元的主要与实验室设备和设施建设相关的固定资产购买[109] - 2023年9月30日,公司融资活动中主要是0.3百万美元的递延发行成本支付,几乎完全抵消了0.2百万美元来自我们的员工购买计划的收入[110] - 2022年9月30日,公司融资活动中主要是0.4百万美元来自我们的员工购买计划的收入[111]